

According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

1. PRODUCT AND COMPANY INFORMATION.

Product Name PictArray™ SARS-CoV-2 ELISA

Product Number PICT-COV-IgG

Relevant identified uses of the substance or mixture and

uses advised against

Identified use(s)

In vitro diagnostic medical device. For

professional use only.

Company Pictor Limited

24 Balfour Road

Parnell

Auckland 1052 New Zealand

Technical Phone +64 9 309 0950 E-mail info@pictordx.com

2. COMPOSITION/ HAZARDS INFORMATION ON INGREDIENTS

The hazards identified with this kit are those associated with the following substances. For additional information, please refer to the individual material safety data sheet(s).

Mixtures

Description: In vitro diagnostic medical device.

Dangerous components: The product does not contain reportable quantities

of dangerous components.

Additional information None.



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

Kit Components

The components contain non-hazardous substances listed in the Table below

Sr.	Component	Hazardous substance	% By weight
no			
1	PictArray™ SARS-CoV-2 ELISA	None	N/A
2	Sample Diluent	None	N/A
3	Wash Buffer	None	N/A
4	Peroxidase Conjugated anti-Human IgG	Sodium Azide	<0.01
5	TMB Substrate	None	N/A
6	Anti-SP Protein control	None	N/A
7	Anti-NP Protein control	None	N/A

3. HAZARDS IDENTIFICATION

Classification of the substance or mixture Regulation (EC) No. 1272/2008 (CLP)

Not Classified as hazardous

Emergency Overview OSHA Hazards

No known OSHA hazards

Not a dangerous substance according to GHS.

Label elements No Measures Required

Other Hazards None

HMIS Classification

Health Hazards: 0
Flammability: 0
Physical hazards: 0

NFPA Rating

Flammability: 0
Fire: 0
Reactivity: 0

Potential Health Effects

Inhalation May be harmful if inhaled. May cause

respiratory tract irritation.

Skin May be harmful if absorbed through skin.

May cause skin irritation.

Eyes May cause eye irritation.
Ingestion May be harmful if swallowed.

Page 2 of 9



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

4. FIRST AID MEASURES



Skin contact Rinse with plenty of water. If symptoms arise, call a doctor.

Eye contact Rinse immediately with plenty of water for at least 15

minutes. If symptoms persist, call a doctor.

Ingestion Wash out mouth with water. Do not induce vomiting without

medical care.

Inhalation Move person to fresh air. If discomfort persists, call a

Most important symptoms and effects,

both acute and delayed

:None known.

:None.

Indication of the immediate medical

attention and special treatment needed

5. FIRE FIGHTING MEASURES

Suitable extinguishing media Water spray and carbon dioxide (CO₂)

foam.

Special protective equipment Wear self-contained breathing apparatus

and protective suit.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions:

Avoid dust formation and avoid breathing vapours, mist, or gas.

Environmental precautions:

Do not let product enter drains.

Methods and materials for containment and cleaning up:

Keep in suitable, closed containers for disposal

7. HANDLING AND STORAGE

Always wear recommended personal protective equipment. Use Handling

gloves when handling. No other special handling advice required.

Store between 2 ° C to 8 ° C Storage



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

8. EXPOSSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment

Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts is desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection



Handle with gloves. Gloves must be inspected prior to use. Use proper gloves removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Eye/Face protection



Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU).

Skin and body protection

Choose body protection in relation to its type, to the concentration and number of dangerous substances, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hygiene measures

General industrial hygiene practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Form Liquid

Colour No data available



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

Safety data

pH 7.5

Melting point/freezing point

No data available

Boiling point No data available

Flash point No data available

Ignition temperature No data available

Autoignition temperature No data available

Lower explosion limit No data available

Upper explosion limit No data available

Vapour pressure No data available

Density No data available

Water solubility No data available

Partial coefficient: No data available

n-octanol/water

Odour No data available

Odour Threshold No data available

Evaporation rate No data available

10. STABILITY AND REACTIVITY

Chemical stability

Stable under recommended storage conditions.

Possibility of hazardous reactions

No data available

Conditions to avoid

No data available

Materials to avoid

Strong oxidizing agents

Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. Nature of decomposition products not known. Other decomposition products- no data available

Page 5 of 9



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

11. TOXICOLOGICAL INFORMATION

Acute Toxicity

Oral LD50 No data available

Inhalation LD50 No data available

Dermal LD50 No data available

Other information on acute toxicity No data available

Skin corrosion/irritation No data available

Serious eye damage/eye irritation No data available

Respiratory or skin sensitization No data available

Germ cell mutagenicity No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to

0.1% is identified as probably, possible or confirmed human carcinogen by

IARC.

ACGIH: No component of this product present at levels greater than or equal to

0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to

0.1% is identified

OSHA: No component of this product present at levels greater than or equal to

0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

No data available

Teratogenicity No data available

Specific target organ toxicity - single exposure (Globally Harmonized System)

no data available

Specific target organ toxicity -repeated exposure (Globally Harmonized System)

no data available



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

12. ECOLOGICAL INFORMATION

Toxicity Data No data available

Persistence and degradability

No data available

Bio accumulative potential No data available

Mobility in soil No data available

PBT and vPBT assessment No data available

Other adverse effects No data available

13. DISPOSAL CONSIDERATIONS

Product Offer surplus and non-recyclable

solutions to a licensed disposal company. Chemical residues and remains should be routinely handled as special waste. This must be disposed of in compliance with antipollution and other laws of the country concerned. To ensure compliance we recommend that you contact the relevant (local) authorities and/or an approved waste disposal

company for information

European waste catalogue: 18 01 07.

Packaging: Disposal should be in accordance with

local, state, or national legislation. Packaging materials may be recycled. Contact your local service providers for

further information.

Contaminated packaging product Dispose unused product.

14. TRANSPORT INFORMATION

Not classified as dangerous in the meaning of transport regulations.

Hazard Class
Subsidiary Class
Data not yet available
Packing Group
Data not yet available
Data not yet available



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

UN Number Transport hazard class(es) Environmental hazards Special precautions for user

Transport in bulk according to Annex II of MARPOL73/78

and the IBC Code

Data not yet available Transport hazard class(es)

Not applicable. Not applicable. Not applicable.

15. REGULATORY INFORMATION

Safety, health, and environmental regulations/ directive legislation specific for the substance or mixture. In Vitro diagnostics medical devices 98/79/EC.
OSHA Hazard Communication Standard.

29 CFR 1910.1200 Consumer

Product Safety Regulations 16 CFR 1600 IVD Product Labelling 21 CFR 809.

R-Phrases R22

R38

Harmful if swallowed



R36 Irritating to eyes



R37 Irritating to the respiratory



Irritating to skin



Page 8 of 9



According to Regulation (EC) No. 1907/2006 (REACH), Annex II

Rev.1 Effective Date: 13-May-2022

S-Phrases

S28 After contact with skin, wash thoroughly

with water.

S37/39 Wear gloves and suitable protective

clothing.

S45 In case of accident or if you feel unwell,

seek immediate medical advice.

16. OTHER INFORMATION

The information provided in this Material Safety Data Sheet is believed to be accurate and does not purport to be all inclusive and shall be used only as a guide. It is the responsibility of the user to determine applicability of these data to formulate necessary safety precautions. Pictor Limited shall not be held liable for any damage resulting from handling or from contact with the above product.

End of the document.

SARS-CoVID-2 SDS (DOC-1222) Ver. 0

Approved By:

(CO-189) SARS-CoVID-2 SDS

Description

SARS-CoVID-2 SDS

Justification

SARS-CoVID-2 SDS

Assigned To:Initiated By:Priority:Impact:Nancy AhirUrgentMajor

Version History:

 Author
 Effective Date
 CO#
 Ver.
 Status

 Nancy Ahir
 May 13, 2022 4:45 PM NZST
 CO-189
 0
 Published